Testing HRS-9813 for progressive pulmonary fibrosis
Part of Lungs & breathing clinical trials.
This trial tests a new drug called HRS-9813 for people with pulmonary fibrosis (scarring in the lungs) that continues to worsen. It looks at whether the drug can slow down the disease compared to a placebo.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 21 or older (for PPF) or 45 or older (for IPF) and have a confirmed diagnosis of pulmonary fibrosis.
- You have had a lung function test showing your FVC is at least 40% of normal and your DLCO is at least 25% of normal.
- If you were taking nintedanib or pirfenidone, you either stopped at least 8 weeks ago or have been on a stable dose for at least 8 weeks.
- You have not had a lung infection, a flare-up of your lung disease, or a hospitalization for heart or lung problems in the last 3 months.
- You do not have severe emphysema, active tuberculosis, uncontrolled heart disease, or a history of lung transplant or certain cancers in the last 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new tablet, HEC585, for people with idiopathic pulmonary fibrosis (IPF). It aims to see if the drug can help improve lung function and slow the disease. Participants must have a confirmed IPF diagnosis and meet specific breathing test results.
This Phase 2 study tests whether HEC585 can slow the decline in lung function in people with progressive fibrosing interstitial lung disease (PF-ILD). It may help preserve breathing capacity and breathing tolerance over time.
This trial tests a new medication called SC1011 taken twice a day, compared to a placebo, to see if it can help people with IPF. It is for patients who were diagnosed within the last 5 years and have moderate lung function.
This study tests a new medication called AK3280 for people with idiopathic pulmonary fibrosis (IPF), a lung condition. The goal is to see if AK3280 can help improve lung function. To join, you must have a confirmed IPF diagnosis and meet certain health criteria.
This trial tests a new medicine called HSK44459 for people with progressive pulmonary fibrosis (PPF). It aims to see if the drug can help slow lung damage and improve breathing. You may join if you are not taking certain other fibrosis drugs or have been on a stable dose for at least 12 weeks.
This study tests whether a new drug called HSK44459 can slow lung scarring (idiopathic pulmonary fibrosis or IPF) and improve your ability to breathe. You'll receive either the drug or a placebo while your lung function is monitored over time.
Hear when a new IPF and PPF trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.